GreenLight Medicines is a biopharmaceutical company established in 2014, headquartered in Ireland. The company focuses on researching, developing, and licensing molecules from proprietary cannabinoid formulations to target various disease areas within the Biopharma and Health Care industries.
GreenLight Medicines' core expertise lies in the development of plant-derived cannabinoid molecules from proprietary strains. Their intellectual property portfolio encompasses proprietary blends of cannabinoids, innovative plant oil extraction processes, and cannabis cultivation technologies (hardware and software).
The €1.80M Corporate Round investment at 07 January 2019 was secured from SOL Global Investments, further endorsing the company's potential and attracting the attention of investors.
With a vision to create 500 research and development jobs in the next five years, GreenLight Medicines is committed to promoting industry awareness and developing environmentally friendly, sustainable medicines, thus elevating shareholder value by expanding into new markets.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | €1.80M | 1 |
|
07 Jan 2019 |
| Seed Round | €500.00K | - | 21 Sep 2016 |
No recent news or press coverage available for GreenLight Medicines.
We care about your data, and we'd love to use cookies make your experience better.